Lately the many similarities between breast and prostate cancer have become widely appreciated [49], leading to important therapeutic implications, such as a phase II clinical trial that is currently underway to investigate the potential benefit of targeting AR in triple negative breast cancer [54]. This evidence concerns the gene AR and prostate cancer.